DiaMedica Therapeutics Announces Expansion Of DM199 Program Into Preeclampsia
Portfolio Pulse from Benzinga Newsdesk
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announced the expansion of its DM199 program into preeclampsia, with a Phase 2 trial starting in Q4 2024 and key results expected in H1 2025. The company will host a conference call on June 27, 2024, and a key opinion leader event on July 29, 2024.
June 26, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DiaMedica Therapeutics is expanding its DM199 program into preeclampsia, with a Phase 2 trial starting in Q4 2024 and key results expected in H1 2025. This could potentially address a significant unmet medical need, as there are no approved therapeutics for preeclampsia in the U.S. or Europe.
The expansion into preeclampsia represents a significant development for DiaMedica Therapeutics, addressing a major unmet medical need. The announcement of a Phase 2 trial and expected results timeline could generate investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100